Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: Bull-like who wrote (440)	12/8/1998 2:58:00 PM
From: Anthony Wong	Read Replies (2) \| Respond to of 642

Several articles say that Prozac's patent expires in 2 stages in 2001 and 2003. The following is an excerpt from a recent Reuters article: For some time, Wall Street has fretted about Lilly's future after Prozac. The drug's patent, which prohibits others from manufacturing it, expires in two stages in 2001 and 2003. That timetable may change, analysts said, depending on the outcome of a patent lawsuit scheduled to come to trial in late January in Indianapolis. Generic drug maker Barr Laboratories Inc. of Pomona, N.Y., is challenging Prozac's patents. From labpuppy.com: Patent expiration of major drugs from big pharmas Eli Lilly (LLY) Humulin - Expired Prozac - 2001 or 2003 (this date is being fought over) Axid - 2002 Gemzar - 2006 Zyprexa - 2011 Evista – 2013

To: Bull-like who wrote (440)	12/11/1998 2:35:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 642

Lilly Drug Cuts Some Breast-Cancer Risk 63% in Study (Update2) Bloomberg News December 11, 1998, 12:34 p.m. ET Lilly Drug Cuts Some Breast-Cancer Risk 63% in Study (Update2) (Adds details of study in 8th and 9th paragraphs, Evista in 11th to 13th paragraphs.) Indianapolis, Dec. 11 (Bloomberg) -- Eli Lilly & Co.'s bone- protecting drug Evista reduced the risk of some breast cancers by 63 percent in a large study, which may boost Evista sales and help offset an expected sales slide of the antidepressant Prozac. Lilly, the sixth largest U.S. drugmaker, said the overall incidence of breast cancer fell 55 percent in the study, in which women took Evista for more than three years. The data will be presented in detail tomorrow at the 21st San Antonio Breast Cancer Symposium. Indianapolis-based Lilly needs to build Evista into a top- selling drug to offset Prozac, which loses patent protection in a few years. Prozac had $2.56 billion in sales last year, or 30 percent of Lilly's 1997 revenue of $8.52 billion. Evista, which generates about 1.1 percent of Lilly's sales, is approved in the U.S. for prevention of thinning of bones, or osteoporosis, in older women. ''The reductions in breast-cancer risk seen to date in these trials are extremely important and provide invaluable information for the additional large-scale testing of Evista in the prevention of breast cancer,'' said Craig Jordan, director of a breast cancer research program at Northwestern University, in a press release. Shares of Lilly, which is continuing with tests of Evista's effects on reducing the risk of breast cancer, rose 2 9/16 to 89 7/16 in early afternoon trading. It earlier touched 91. The Wall Street Journal first reported the breast-cancer reduction this morning. Lilly also said the U.S. Food and Drug Administration will let it put information about Evista's potential to reduce breast- cancer risk on the label. This is not a new indication for the drug, Lilly said. The label will include early data from studies that showed a more than 50 percent decrease in the incidence of breast cancer among post-menopausal women taking Evista compared to those given a placebo. The label also will note that women in these studies had regular mammograms. The data Lilly will present tomorrow in San Antonio comes from 10,575 women who were enrolled in 10 different tests of Evista as a bone-protecting drug. The company is performing studies aimed at letting it seek FDA permission to expand the approved use of Evista to breast cancer prevention. It also is testing whether Evista can prevent heart disease in older women. Evista is the first of a new class of drugs that have been called ''estrogen light.'' It appears to offer some of the benefits of estrogen with fewer side effects. Evista appears to work by acting on some of the body parts estrogen helps, such as bones and the heart. Its chemical shape, though, may block estrogen in the uterus and the breast. Long- term use of estrogen may be linked to breast cancer. Evista also doesn't have some of the benefits of replacement estrogen therapy, such as easing symptoms of menopause. Other drugmakers are trying to make similar products to Evista. SmithKline Beecham Plc has a drug in the last of three stages of testing required to apply for FDA approval. Pfizer has two likely compounds for its ''estrogen light'' drug. --Kerry Dooley in the Princeton newsroom (609) 279-